The demand for masculinizing breast surgery and hysterectomy with bilateral salpingo-oophorectomy (HBSO) from transmen has increased. With a multidisciplinary approach, these surgeries can be performed in a single session. The objective of this study was to retrospectively evaluate the feasibility, safety, and satisfaction of HBSO and chest surgery in transmen. A cohort of 142 subjects who underwent HBSO alone or combined with chest surgery at Sant’Orsola Hospital was analyzed. Intra and post operation events were evaluated. Subjective post-intervention satisfaction, acceptability, and impact of intervention were assessed via a semi-structured interview. Nineteen transmen underwent HBSO alone and 123 underwent combined surgery. HBSO was performed laparoscopically in 96.5% of transmen (137/142). As expected, length of hospital stay and blood loss were significantly higher in the combined surgery group. A total of 13 intra or post-operative complications occurred in the combined surgery group (10.5%) with thoracic hematoma being the most frequent complication (7.6%). Only one rare complication occurred in the HBSO group (omental herniation through a laparoscopic breach). The overall subjective satisfaction score was 9.9 out of 10 for both groups. Positive changes in all areas of life were reported, with no significant differences. We found that the combined surgery appears to be well tolerated, safe, and feasible in transmen and satisfaction with the combined procedure was high in all subjects.
Background: Genitourinary syndrome of menopause (GSM) is a condition affecting many postmenopausal women. Among the available treatments, the vaginal natural oxygenation device (VNOD) is a new promising option. Aim: To evaluate the safety and the effectiveness of vaginal high concentration (HC) oxygen (O 2 ) and hyaluronic acid (HA) in postmenopausal women with vaginal atrophy (VA). Methods: Study 1: Ten subjects received HA and O 2 at a concentration of 21% (sham group) and ten at 95% (treatment group). All subjects completed five sessions of VNOD. Evaluations and questionnaires were completed at baseline, before each session and at one-month follow-up: Visual Analogue Scale, Vaginal Health Index (VHI), Vaginal Maturation Value (VMV), Menopause Quality Of Life (MeNQoL), Female sexual function index (FSFI) and Female sexual distress scale (FSDS). Study 2: 52 postmenopausal women with VA completed the same protocol of study 1 with HC O 2 and HA. Results: Treatment was well-tolerated. In study 1, in the treatment group we recorded significant improvements in VHI score ( p -value 0.001), VMV ( p -value 0.005) and in the psychosocial, physical and sexual domains of the MeNQoL compared to sham group. In study 2, all women experienced a significant improvement in VHI ( p -value <0.001), FSFI total score ( p -value 0.007), desire ( p -value 0.004), lubrication ( p -value 0.006), satisfaction ( p -value 0.042), pain ( p -value 0.001) domains, FSDS score ( p -value 0.003) and MeNQoL sexual domain ( p -value <0.001). Conclusion: The preliminary results of this study suggest that VNOD is a safe and effective treatment for VA in postmenopausal women, and improves sexual function.
Background and Objectives: The aim of this study was to investigate lifestyle, menopausal symptoms, depression, post-traumatic stress disorder (PTSD) and sleep disorders in post-menopausal women throughout the first wave of the COVID-19 pandemic, including the impact of menopause hormonal therapy (HT). Materials and Methods: Post-menopausal women were given the following questionnaires: socio-demographic characteristics; lifestyle; history of COVID-19; menopause-specific quality of life (MENQOL), the first part of which refers to the pre-pandemic period (“pre COVID-19”) and the second refers to the current period (“during COVID-19”); Beck’s depression inventory (BDI); the impact of event scale-revised (IES-R); and the Pittsburgh sleep quality index (PSQI). Results: One hundred and twenty-six women completed all questionnaires, with a mean age of 55.5 ± 6.0 years. The mean menopause duration was 5.7 ± 5.6 years. Twenty-four women were taking HT. A significant mean weight gain, a reduction in physical activity (respectively p < 0.001) and worsened quality of romantic relationships (p = 0.001) were reported during the pandemic. Menopausal symptoms did not vary significantly throughout the pandemic; however, women taking menopausal HT had lower physical (p = 0.003) and sexual (p = 0.049) MENQOL domain scores, lower depressive symptoms (p = 0.039) and better romantic relationships (p = 0.008). Conclusions: The COVID-19 pandemic caused reduced physical activity, worsened food habits and weight gain in post-menopausal women. They also reported a high rate of severe–moderate PTSD and a negative influence on their romantic relationships. Menopausal HT seems to be a potential protective factor for sexual and physical status and for symptoms of depression.
ObjectiveTo evaluate the impact of a short-term cognitive-behavioural therapy (CBT) protocol on menopausal symptoms and quality of life in women undergoing menopause.Study DesignA short-term individual CBT protocol was developed. Peri- and post-menopausal women with symptoms were enrolled and assigned to either the experimental group (CBT) or the waitlist (CTL group) by patient's decision.Main Outcome MeasureThree validated questionnaires were used to assess psychological well-being before (T1) and after (T2) the intervention: the Menopausal Rating Scale (MRS), Clinical Outcomes in Routine Evaluation - Outcome Measure (Core-OM), and the World Health Organization Quality of Life in the short version (WHOQOL-BREF).ResultsForty-eight women were included, 24 in each group. At T1, the CBT group had worse scores than the CTL group across all questionnaires. At T2, the CBT group showed significant improvement in all measures, while the CTL group experienced significant worsening in CORE-OM and WHOQOL-BREF scores, with stable MRS scores. In the MRS, at T2 the CBT group showed significant reduction in both the psychological and somatic sub-domains (<0.001), while the CTL group's scores remained unchanged. In the CORE-OM, the CBT group showed significant improvement in the well-being (p = .002), problems (p = .005), and functioning (p = .001) sub-domains, while the CTL group had significant declines. In the WHOQOL-BREF, the CBT group demonstrated significant improvements in all domains (p < .001), while the CTL group declined.ConclusionA short-term tailored individual CBT protocol is effective in managing menopausal symptoms, helping women develop the resources and coping strategies needed to adjust to this complex period.